# 日本的 Shionogi & Co 週一表示，美國食品藥物管理局已批准其口服抗病毒藥物 Ensitrelvir。

*biotech · news · 2026-06-02 · Newsmax*

## Key points

- FDA 批准了 Shionogi 的口服抗病毒藥物 Xocova 用於 COVID-19 暴露後預防。
- Xocova 是首個經證實能在暴露後預防有症狀 COVID-19 的口服藥物。
- Xocova 的有效性不受參與者疫苗接種狀況影響。
- Shionogi 的財務預測已考慮到 Xocova 在 2027 年 3 月前獲 FDA 批准的影響。

Japan's Shionogi & ‌Co said on Monday the U.S. Food and Drug Administration has approved its oral antiviral Ensitrelvir, commercially ‌known as Xocova, for ​the preventive treatment of individuals who have been ⁠exposed to COVID-19. "XOCOVA is ​the first and only oral ⁠option clinically proven to help prevent symptomatic COVID-19 after exposure among ‌study participants regardless of ​vaccination status," Nathan McCutcheon, ‌CEO of Shionogi's U.S. unit, ‌said in a statement. The financial impact of the FDA ⁠approval of ‌Xocova in ⁠the current fiscal year ending March ⁠2027 ⁠has already been reflected in the earnings ‌forecast announced last month, Shionogi said. Shionogi shares were down ‌4.5% ​on Monday, ‌while the benchmark Nikkei 225 index was up 0.9%.

**Companies:** Shionogi & Co
**Countries:** Japan, United States

[Read the full story on Newsmax](https://www.newsmax.com/health/health-news/covid-fda-oral/2026/06/02/id/1258245/)

---

Canonical: https://newsio.io/zh-TW/n/c9798494-bc65-4562-b22d-b269a603b2c9/shionogi-co-ensitrelvir
Summarized by Newsio from Newsmax. https://newsio.io/how-it-works